Perceptive Advisors IRD Position
ActivePerceptive Advisors held their position in Opus Genetics, Inc. (IRD) in Q4 2025, holding $8.7M worth of shares across 4,325,000 shares.
The position was first reported in Q1 2025 and has been tracked across 4 quarterly 13F filings.
There is an upcoming Phase 2 readout for AAV8.hLCA5 in 791 days (Jun 15, 2028), making the timing of Perceptive's position particularly relevant.
About Opus Genetics, Inc.
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
Full company profile →Short Interest
3.0%
1.8 days to cover
Perceptive Advisors IRD Position History
Frequently Asked Questions
Does Perceptive Advisors own IRD?
Yes. As of Q4 2025, Perceptive Advisors holds 4,325,000 shares of Opus Genetics, Inc. (IRD) valued at $8.7M. This data comes from their SEC 13F filing.
How many hedge funds own IRD?
1 specialist biotech hedge fund currently holds IRD. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Perceptive Advisors first buy IRD?
Perceptive Advisors's position in IRD was first reported in Q1 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Perceptive Advisors's IRD position increasing or decreasing?
Perceptive Advisors held their IRD position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
IRDCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Perceptive AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →